Recommended Articles
Fundraising

Opentrons Raises $40 Million Series E for AI-Driven Lab Automation

By Angeled · October 31, 2026 · Fundraising
Opentrons Raises $40 Million Series E for AI-Driven Lab Automation
Opentrons Raises $40 Million Series E for AI-Driven Lab Automation

Opentrons Labworks Inc. announced on October 29, 2026, that it has raised $40 million in a Series E financing round led by healthcare investor Avego, with additional investment from BroadOak Capital Partners. Existing investors include SoftBank Vision Fund and Khosla Ventures.

The company, headquartered in New York City, will use the capital to scale its robotics, software, and data infrastructure tools, and to advance its next phase of growth in what it calls autonomous science: systems in which AI and robotics work together to design, execute, and learn from experiments.

What Opentrons Builds

Opentrons builds open, API-driven laboratory robots that automate the physical work of biological experimentation: moving liquids, preparing samples, and running protocols that scientists previously performed by hand. Its flagship platform, Opentrons Flex, combines laboratory robots with software and AI tools intended to create a feedback loop in which experiments can be designed, carried out, and refined using the results of previous runs.

The company says it has more than 11,000 robots deployed worldwide, including at every top-20 U.S. research university and 14 of the top 15 global biopharma companies. That installed base is the core of its pitch. In laboratory automation, the hardware is only half the story; the other half is standardization. When thousands of labs run experiments on the same robots with the same software, their results become comparable, and the data those experiments generate becomes usable for training AI models.

Opentrons was founded in 2014. Its backers also include Sands Capital, Lerer Hippeau, and Y Combinator. The company did not disclose its valuation following the Series E.

What "Autonomous Science" Means

The term "autonomous science" describes a loop with four stages. An AI model proposes an experiment, a robot executes it, instruments record the results, and the model updates its understanding and proposes the next experiment. Humans set the goal and review the results, but the cycle of trial and refinement runs with less manual intervention.

This matters because modern biology is increasingly a data problem. Drug discovery, genomics, and synthetic biology all depend on running large numbers of experiments and learning from the results. Manual lab work is slow, expensive, and variable: two scientists following the same protocol can get different results. Automation reduces that variability, and standardized automation produces the clean, structured datasets that AI models need.

Opentrons' bet is that the company that owns the execution layer — the robots and software that actually run the experiments — will own the data layer too, and therefore be central to AI-driven discovery.

Why This Round, and Why Now

Laboratory automation has been consolidating around a few themes: AI-designed experiments, cloud-connected instruments, and robotics-as-a-service. Opentrons is positioning itself as the open alternative in this market. Its robots are API-driven, meaning developers can program them with code rather than being locked into a single vendor's software. That openness has helped it spread through academic labs, which are price-sensitive and value flexibility.

The Series E proceeds will fund AI-driven experiment execution, additional automation capabilities, deeper integration across laboratory systems, and expansion into new markets and geographies. In practice, that means more software, more instrument capabilities, and better data infrastructure — the unglamorous plumbing that determines whether an "autonomous lab" actually works day to day.

What It Means for Founders and Investors

For founders in life-science tools, Opentrons offers two lessons. First, distribution through an installed base is a durable advantage: 11,000 robots in the field is a channel that a pure-software startup cannot easily replicate. Second, openness can be a strategy, not just a philosophy. By making its robots programmable, Opentrons turned academic labs — a market with little money but enormous influence — into its early adopters and evangelists.

For investors, the open questions are execution-related. The company has not disclosed this round's valuation, and whether its AI execution loop is already working at scale, rather than in demonstrations, remains to be proven. Laboratory automation is also capital-intensive: hardware must be manufactured, shipped, installed, and supported. The $40 million gives Opentrons room to scale, but the path to profitability in hardware-plus-software life-science tools is longer than in pure software.

Angeled.com connects founders with investors.

Source: opentrons.com
Opentrons, "Opentrons Announces $40M Series E Round to Standardize AI-Driven Science on Its Robots,"
Source: pulse2.com
Pulse2, "Opentrons Raises $40 Million Series E To Expand AI-Driven Laboratory Automation,"
Source: citybiz.co
Citybiz, "Opentrons Raises $40 Million Series E Led by Avego to Expand AI-Driven Lab Automation,"
Source: techstartups.com
TechStartups, "Startup Funding News Today, October 30, 2026,"

Read Next